Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | PRKACG | P22612 | 1/20 | 0.51 |
| ▸ | PRKACB | P22694 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 17/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8317402 | 0.90 | SIRT2 (0.63) | SIRT2SIRT1CCNE2CDK4PRKACA | |
| SCHEMBL5333444 | 0.90 | SIRT2 (0.52) | SIRT2SIRT1CCNE2CDK4PRKACA | |
| SCHEMBL5343477 | 0.81 | SIRT2 (0.80) | SIRT2SIRT1CCNE2CDK4PRKACA | |
| SCHEMBL20624204 | 0.79 | SIRT2 (0.63) | SIRT2SIRT1CCNE2CDK4PRKACA | |
| SCHEMBL7195501 | 0.79 | SIRT2 (0.63) | SIRT2SIRT1CCNE2CDK4PRKACA | |
| SCHEMBL14440430 | 0.79 | SIRT2 (0.63) | SIRT2SIRT1CCNE2CDK4PRKACA | |
| SCHEMBL7193750 | 0.77 | SIRT2 (0.54) | SIRT2SIRT1HTR6IDO1 | |
| SCHEMBL5339298 | 0.77 | CDK4 (0.57) | SIRT2CCNE2CDK4PRKACAPRKACG | |
| SCHEMBL5332724 | 0.75 | ALDH1A1 (0.52) | SIRT2SIRT1CDK4CCND1 | |
| SCHEMBL5334873 | 0.74 | SIRT2 (0.50) | SIRT2SIRT1CCNE2CDK4PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202255-B2 | Substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2007-04-10 | — | — | US | disclosed |
| EP-1587810-B1 | NOVEL SUBSTITUTED 1,4|BENZODIOXINO 2,3-E|ISOINDOLE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2006-11-08 | — | — | EP | disclosed |
| US-20060040930-A1 | Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040930-A1 | Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same | CYP11B2, CYP2F1, CYP3A43 | SIRT2 2042/4885SIRT1 2459/4885CCNE2 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.